Cornerstone Therapeutics, Inc. (CRTX) Misses Q3 EPS by 1c, Sales Fall Below Expectations
Tweet
Share
E-mailGet Alerts CRTX Hot Sheet
Price: $1.95 --0%
Financial Fact:
Total costs and expenses: 37.66M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Total costs and expenses: 37.66M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) reported Q3 non-GAAP EPS of $0.13, $0.01 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $25.18 million versus the consensus estimate of $28.39 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
